FDA Inspection 1268116 — Guangxi Yulin Pharmaceutical Group Co. Ltd.
The FDA completed an inspection of Guangxi Yulin Pharmaceutical Group Co. Ltd. on Mar 21, 2025 in Yulin. The inspection was classified OAI (Official Action Indicated — regulatory and/or administrative actions are recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI)
- End Date
- Mar 21, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Yulin (China)